iTeos Therapeutics, Inc.

NasdaqGM ITOS

iTeos Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025

iTeos Therapeutics, Inc. Price to Sales Ratio (P/S) is NA on January 14, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

iTeos Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
iTeos Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
iTeos Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: ITOS

iTeos Therapeutics, Inc.

CEO	Dr. Michel Detheux Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Arsenal Street
Employees	157
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Key trends

Past 5 years